Emcyt

How often in a day do you take medicine? How many times?
advertisement

Emcyt uses


INDICATIONS AND USAGE

Emcyt Capsules are indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.

CONTRAINDICATIONS

Emcyt Capsules should not be used in patients with any of the following conditions:

WARNINGS

It has been shown that there is an increased risk of thrombosis, including fatal and nonfatal myocardial infarction, in men receiving estrogens for prostatic cancer. Emcyt Capsules should be used with caution in patients with a history of thrombophlebitis, thrombosis, or thromboembolic disorders, especially if they were associated with estrogen therapy. Caution should also be used in patients with cerebral vascular or coronary artery disease.

Glucose Tolerance-Because glucose tolerance may be decreased, diabetic patients should be carefully observed while receiving Emcyt.

Elevated Blood Pressure-Because hypertension may occur, blood pressure should be monitored periodically.

PRECAUTIONS

General

Fluid Retention. Exacerbation of preexisting or incipient peripheral edema or congestive heart disease has been seen in some patients receiving therapy with Emcyt Capsules. Other conditions which might be influenced by fluid retention, such as epilepsy, migraine, or renal dysfunction, require careful observation.

Emcyt may be poorly metabolized in patients with impaired liver function and should be administered with caution in such patients.

Because Emcyt may influence the metabolism of calcium and phosphorus, it should be used with caution in patients with metabolic bone diseases that are associated with hypercalcemia or in patients with renal insufficiency. Patients with prostate cancer and osteoblastic metastases are at risk for hypocalcemia and should have calcium levels closely monitored.

Gynecomastia and impotence are known estrogenic effects.

Allergic reactions and angioedema at times involving the airway have been reported.

Information for the Patient

Because of the possibility of mutagenic effects, patients should be advised to use contraceptive measures.

Laboratory Tests

Certain endocrine and liver function tests may be affected by estrogen-containing drugs. Emcyt may depress testosterone levels. Abnormalities of hepatic enzymes and of bilirubin have occurred in patients receiving Emcyt. Such tests should be done at appropriate intervals during therapy and repeated after the drug has been withdrawn for two months.

Food/Drug Interaction

Milk, milk products, and calcium-rich foods or drugs may impair the absorption of Emcyt.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term continuous administration of estrogens in certain animal species increases the frequency of carcinomas of the breast and liver. Compounds structurally similar to Emcyt are carcinogenic in mice. Carcinogenic studies of Emcyt have not been conducted in man. Although testing by the Ames method failed to demonstrate mutagenicity for Emcyt phosphate sodium, it is known that both estradiol and nitrogen mustard are mutagenic. For this reason and because some patients who had been impotent while on estrogen therapy have regained potency while taking Emcyt, the patient should be advised to use contraceptive measures.

advertisement

ADVERSE REACTIONS

In a randomized, double-blind trial comparing therapy with Emcyt Capsules in 93 patients (11.5 to 15.9 mg/kg/day) or diethylstilbestrol (DES) in 93 patients (3.0 mg/day), the following adverse effects were reported:

Emcyt

n=93

DES

n=93

CARDIOVASCULAR-RESPIRATORY
Cardiac Arrest 0 2
Cerebrovascular Accident 2 0
Myocardial Infarction 3 1
Thrombophlebitis 3 7
Pulmonary Emboli 2 5
Congestive Heart Failure 3 2
Edema 19 17
Dyspnea 11 3
Leg Cramps 8 11
Upper Respiratory Discharge 1 1
Hoarseness 1 0
GASTROINTESTINAL
Nausea 15 8
Diarrhea 12 11
Minor Gastrointestinal Upset 11 6
Anorexia 4 3
Flatulence 2 0
Vomiting 1 1
Gastrointestinal Bleeding 1 0
Burning Throat 1 0
Thirst 1 0
INTEGUMENTARY
Rash 1 4
Pruritus 2 2
Dry Skin 2 0
Pigment Changes 0 3
Easy Bruising 3 0
Flushing 1 0
Night Sweats 0 1
Fingertip-Peeling Skin 1 0
Thinning Hair 1 1
BREAST CHANGES
Tenderness 66 64
Enlargement
Mild 60 54
Moderate 10 16
Marked 0 5
MISCELLANEOUS
Lethargy Alone 4 3
Depression 0 2
Emotional Lability 2 0
Insomnia 3 0
Headache 1 1
Anxiety 1 0
Chest Pain 1 1
Hot Flashes 0 1
Pain in Eyes 0 1
Tearing of Eyes 1 1
Tinnitus 0 1
LABORATORY ABNORMALITIES
Hematologic
Leukopenia 4 2
Thrombopenia 1 2
Hepatic
Bilirubin Alone 1 5
Bilirubin and LDH 0 1
Bilirubin and SGOT 2 1
Bilirubin, LDH and SGOT 2 0
LDH and/or SGOT 31 28
Miscellaneous
Hypercalcemia-Transient 0 1
advertisement

OVERDOSAGE

Although there has been no experience with overdosage to date, it is reasonable to expect that such episodes may produce pronounced manifestations of the known adverse reactions. In the event of overdosage, the gastric contents should be evacuated by gastric lavage and symptomatic therapy should be initiated. Hematologic and hepatic parameters should be monitored for at least 6 weeks after overdosage of Emcyt Capsules.

DOSAGE AND ADMINISTRATION

The recommended daily dose is 14 mg per kg of body weight (ie, one 140 mg capsule for each 10 kg or 22 lb of body weight), given in 3 or 4 divided doses. Most patients in studies in the United States have been treated at a dosage range of 10 to 16 mg per kg per day.

Patients should be instructed to take Emcyt Capsules at least 1 hour before or 2 hours after meals. Emcyt should be swallowed with water. Milk, milk products, and calcium-rich foods or drugs (such as calcium-containing antacids) must not be taken simultaneously with Emcyt.

Patients should be treated for 30 to 90 days before the physician determines the possible benefits of continued therapy. Therapy should be continued as long as the favorable response lasts. Some patients have been maintained on therapy for more than 3 years at doses ranging from 10 to 16 mg per kg of body weight per day.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1–8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

HOW SUPPLIED

White opaque capsules, each containing Emcyt phosphate sodium as the disodium salt monohydrate equivalent to 140 mg Emcyt phosphate-bottle of 100 (NDC 0013-0132-02).

NOTE

Emcyt Capsules should be stored in the refrigerator at 36° to 46°F (2° to 8°C).

REFERENCES


Rx only

LAB-0088-4.0

June 2007

Pfizer

NDC 0013-0132-02

Emcyt ®

capsules

140 mg*

Emcyt phosphate

sodium capsules

100 Capsules

Rx only

advertisement

Emcyt pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Emcyt available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Emcyt destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Emcyt Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Emcyt pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. "estramustine". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  2. "estramustine". http://www.drugbank.ca/drugs/DB0119... (accessed August 28, 2018).
  3. "35LT29625A: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Dat... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Emcyt?

Depending on the reaction of the Emcyt after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Emcyt not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Emcyt addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Emcyt, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Emcyt consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2024 "sdrugs.com". All Rights Reserved